Advertisement

French translation and normation of the Parkinson neuropsychometric dementia assessment (PANDA)

      Abstract

      Introduction

      Cognitive impairment and depressive symptoms caused by Parkinson's disease (PD) are often underestimated in routine clinical practice, partly due to the lack of short screening tests. The “Parkinson Neuropsychometric Dementia Assessment” (PANDA) is a new convenient tool, validated in German, to assess cognition in PD. It consists of five cognitive tasks and a brief mood questionnaire, and is designed for the early detection of mild cognitive deficits as well as dementia.

      Aims

      To translate the PANDA into French and provide normative data for a French speaking population.

      Methods

      The translation was made by means of the translation/re-translation method. The normation was conducted with 61 control subjects (CS). The Mini Mental State Examination (MMSE) was administered concurrently. A comparison was made with the original study's control group (CG) to determine whether the German algorithms for converting the raw scores could also be used with the French version or whether a new procedure had to be developed. All statistics were conducted with SPSS Statistics18.

      Results

      There is a significant correlation between the PANDA total score and MMSE (r=0.42, p=0.001). Analysis of the total converted scores shows no significant correlation with age (r=0.19; p=0.14). After correction for education, there is no significant difference between our CS and the original study's CG (t=1.50; p=0.14).

      Conclusions

      Our results indicate that the PANDA French translation can be used with the same transformation algorithms as the German version, when adding a correction for education.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Emre M.
        • Aarsland D.
        • Brown R.
        • Burn D.J.
        • Duyckaerts C.
        • Mizuno Y.
        • et al.
        Clinical diagnostic criteria for dementia associated with Parkinson's disease.
        Mov Disord. 2007; 22: 1689-1707
        • Elgh E.
        • Domellöf M.
        • Linder J.
        • Edström M.
        • Stenlund H.
        • Forsgren L.
        Cognitive function in early Parkinson's disease: a population-based study.
        Eur J Neurol. 2009 December; 16: 1278-1284
        • Aarsland D.
        • Bronnick K.
        • Williams-Gray C.
        • Weintraub D.
        • Marder K.
        • Kulisevsky J.
        • et al.
        Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis.
        Neurology. 2010; 12: 1062-1069
        • Aarsland D.
        Epidemiology of dementia associated with Parkinson's disease.
        in: Emre M. Cognitive impairment and dementia in Parkinson's disease. Oxford University Press, New-York2010: 5-14
        • Williams-Gray C.
        • Evans J.
        • Goris A.
        • Foltynie T.
        • Ban M.
        • Robbins T.
        • et al.
        The distinct cognitive syndromes of Parkinson's disease: 5 years follow-up of the CamPaIGN cohort.
        Brain. 2009; 132: 2958-2969
        • Aarsland D.
        • Andersen K.
        • Larsen J.P.
        • Lolk A.
        • Kragh-Sorensen P.
        Prevalence and characteristics of dementia in Parkinson's disease: an 8-year prospective study.
        Arch Neurol. 2003; 60: 387-392
        • Maidment I.
        • Fox C.
        • Boustani M.
        Cholinesterase inhibitors for Parkinson's disease dementia.
        Cochrane Database Sys Rev. 2006; 25
        • Olin J.T.
        • Aarsland D.
        • Meng X.
        Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living.
        Dement Geriatr Cogn Disord. 2010; 29: 510-515
        • Aarsland D.
        • Ballard C.
        • Walker Z.
        • Bostrom F.
        • Alves G.
        • Kossakowski K.
        • et al.
        Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
        Lancet Neurol. 2009 July; 8: 613-618
        • Emre M.
        • Tsolaki M.
        • Bonuccelli U.
        • Tolosa E.
        • Kutzeinigg A.
        • Ceballos-Baumann A.
        • et al.
        Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.
        Lancet Neurol. 2010 Oct; 9: 969-977
        • Riedel O.
        • Heuser I.
        • Klotsche J.
        • Dodel R.
        • Wittchen H.U.
        • GEPAD Study Group
        Occurrence risk and structure of depression in Parkinson disease with and without dementia: results from the GEPAD Study.
        J of Geriatr Psychiatr and Neurol. 2010; 23: 27-34
        • Poewe W.
        Non-motor symptoms in Parkinson's disease.
        Eur J Neurol. 2008; 15: 14-20
        • Folstein M.F.
        • Folstein S.E.
        • McHughes P.R.
        Mini-mental state—practical method for grading the cognitive state of patients for the clinician.
        J Psychiatr Res. 1975; 12: 189-198
        • Nasreddine Z.S.
        • Phillips N.A.
        • Bédirian V.
        • Charbonneau S.
        • Whitehead V.
        • Collin I.
        • et al.
        The Montreal CognitiveAssessment, MoCa: a brief screening tool for mild cognitive impairment.
        J Am Geriatr Soc. 2005; 53: 695-699
        • Mahieux F.
        • Michelet D.
        • Manifacer M.J.
        • Boller F.
        • Fermanian J.
        • Guillard A.
        Mini-Mental Parkinson: first validation study of a new bedside test constructed for Parkinson's disease.
        Behav Neurol. 1995; 8: 15-22
        • Marinus J.
        • Visser M.
        • Verwey N.A.
        • Verhey F.
        • Middelkoop H.A.
        • Stiggelbout A.M.
        • et al.
        Assessment of cognition in Parkinson's disease.
        Neurology. 2003; 61: 1222-1228
        • Kalbe E.
        • Calabrese P.
        • Kohn N.
        • Hilker R.
        • Riedel O.
        • Wittchen H.U.
        • et al.
        Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument.
        Parkinsonism and Relat Dis. 2008; 14: 93-101
        • Kalbe E.
        • Riedel O.
        • Kohn N.
        • Dodel R.
        • Calabrese P.
        • Kessler J.
        Sensitivität und Spezifität des « Parkinson neuropsychometric dementia assessment (PANDA) » : Ergebnisse der GEPAD-Studie.
        Aktuelle Neurol. 2007; 34: 140-146
        • Riedel O.
        • Klotsche J.
        • Spottke A.
        • Deuschl G.
        • Förstl H.
        • Henn F.
        • et al.
        Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD).
        J Neurol. 2008; 255: 255-264
        • Acquadro C.
        • Jambon B.
        • Ellis D.
        • Marquis P.
        Language and translation issues.
        in: Spilker B. Quality of life and pharmacoeconomics in clinical trials. Lippincott-Raven, Philadelphia1996: 575-585
        • New B.
        • Pallier C.
        • Brysbaert M.
        • Ferrand L.
        Lexique 2: a new French Lexical Database.
        Behav Res Methods, Instruments, & Comp. 2004; 36: 516-524
        • Barberger-Gateau P.
        • Commenges D.
        • Gagnon M.
        • Letenneur L.
        • Sauvel C.
        • Dartigues J.
        Instrumental activities of daily living as a screening tool for cognitive impairment and dementia in elderly community dwellers.
        J Am Geriatr Soc. 1992; 40: 1129-1134
        • Kalbe E.
        • Kessler J.
        • Calabrese P.
        • Smith R.
        • Passmore A.P.
        • Brand M.
        • et al.
        DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia.
        Int J of Geriatr Psychiatr. 2004; 19: 136-143
        • Bleecker M.L.
        • Bolla-Wilson K.
        • Kawas C.
        • Agnew J.
        Age‐specific norms for the Mini‐Mental State Exam.
        Neurology. 1988 October; 38: 1565-1568
        • Crum R.M.
        • Anthony J.C.
        • Basset S.S.
        • Folstein M.F.
        Population-based norms for the Mini-Mental State Examination by age and educational level.
        J of the Am Med Association. 1993 May; 18: 2386-2391
        • Grigoletto F.
        • Zappalà G.
        • Anderson D.W.
        • Lebowitz B.D.
        Norms for the Mini-Mental State Examination in a healthy population.
        Neurology. 1999 July; 53: 315-320
        • Lechevallier-Michel N.
        • Fabrigoule C.
        • Lafont S.
        • Letenneur L.
        • Dartigues J.F.
        Normes pour le MMSE, le test de rétention visuelle de Benton, le set test d'Isaacs, le sous-test des codes de la WAIS et le test de barrage de Zazzo chez des sujets âgés de 70 ans et plus : données de la cohorte PAQUID.
        Rev Neurol. 2004; 160: 1059-1070